Remission of adult-onset asthma is rare: a 15-year follow-up study.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
28
08
2020
accepted:
12
09
2020
entrez:
2
12
2020
pubmed:
3
12
2020
medline:
3
12
2020
Statut:
epublish
Résumé
There are few long-term clinical follow-up studies of adult-onset asthma. The aim of this article was to study clinical characteristics of adult-onset asthma in relation to remission and persistence of the disease in a 15-year follow-up. A cohort of 309 adults aged 20-60 years with asthma onset during the last 12 months verified by bronchial variability, was recruited between 1995 and 1999 from the general population in northern Sweden. The cohort was followed-up in 2003 (n=250) and between 2012 and 2014 (n=205). Structured interviews and spirometry were performed at recruitment and the follow-ups. Bronchial hyperreactivity (BHR) and skin-prick tests were performed at recruitment and blood samples were collected at the last follow-up. Remission of asthma was defined as no asthma symptoms and no use of asthma medication during the last 12 months. Of eight individuals in remission in 2003, five had relapsed between 2012 and 2014 and in total, 23 (11%) were in remission, while 182 had persistent asthma. Those in remission had higher mean forced expiratory volume in 1 s % predicted at recruitment than those with persistent asthma (94.6 Higher forced expiratory volume in 1 s % predicted and less-severe BHR was associated with remission of adult-onset asthma, but still, the proportion in remission in this 15-year follow-up was low.
Sections du résumé
BACKGROUND
BACKGROUND
There are few long-term clinical follow-up studies of adult-onset asthma. The aim of this article was to study clinical characteristics of adult-onset asthma in relation to remission and persistence of the disease in a 15-year follow-up.
METHODS
METHODS
A cohort of 309 adults aged 20-60 years with asthma onset during the last 12 months verified by bronchial variability, was recruited between 1995 and 1999 from the general population in northern Sweden. The cohort was followed-up in 2003 (n=250) and between 2012 and 2014 (n=205). Structured interviews and spirometry were performed at recruitment and the follow-ups. Bronchial hyperreactivity (BHR) and skin-prick tests were performed at recruitment and blood samples were collected at the last follow-up. Remission of asthma was defined as no asthma symptoms and no use of asthma medication during the last 12 months.
RESULTS
RESULTS
Of eight individuals in remission in 2003, five had relapsed between 2012 and 2014 and in total, 23 (11%) were in remission, while 182 had persistent asthma. Those in remission had higher mean forced expiratory volume in 1 s % predicted at recruitment than those with persistent asthma (94.6
CONCLUSION
CONCLUSIONS
Higher forced expiratory volume in 1 s % predicted and less-severe BHR was associated with remission of adult-onset asthma, but still, the proportion in remission in this 15-year follow-up was low.
Identifiants
pubmed: 33263024
doi: 10.1183/23120541.00620-2020
pii: 00620-2020
pmc: PMC7680910
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright ©ERS 2020.
Déclaration de conflit d'intérêts
Conflict of interest: L. Almqvist has nothing to disclose. Conflict of interest: E. Rönmark has nothing to disclose. Conflict of interest: C. Stridsman has nothing to disclose. Conflict of interest: H. Backman reports speaking fees from Boehringer Ingelheim and AstraZeneca outside the submitted work. Conflict of interest: A. Lindberg reports personal fees for lectures and an advisory board from Boehringer Ingelheim, personal fees for an advisory board from AstraZeneca, personal fees for lectures from Novartis, and personal fees for an advisory board from GlaxoSmithKline, outside the submitted work. Conflict of interest: B. Lundbäck reports personal fees for participating at advisory board meetings from GSK and Sanofi, outside the submitted work. Conflict of interest: L. Hedman has nothing to disclose.
Références
J Allergy Clin Immunol. 2011 Sep;128(3):508-15.e1-2
pubmed: 21782230
Pulm Pharmacol Ther. 2013 Aug;26(4):455-8
pubmed: 22609067
Respir Med. 2011 Oct;105(10):1449-56
pubmed: 21600752
Eur Respir J. 2005 Feb;25(2):282-8
pubmed: 15684292
Am Rev Respir Dis. 1979 May;119(5):831-8
pubmed: 453705
Eur Respir J. 2002 Apr;19(4):599-605
pubmed: 11998986
Eur Clin Respir J. 2015 Jul 20;2:
pubmed: 26557250
Expert Rev Respir Med. 2016;10(1):39-51
pubmed: 26610152
Clin Transl Allergy. 2012 Jan 04;2(1):1
pubmed: 22409857
BMJ. 1996 May 11;312(7040):1195-9
pubmed: 8634562
J Allergy Clin Immunol. 2012 Jan;129(1):136-42
pubmed: 21975174
Eur Respir J. 2003 Mar;21(3):468-72
pubmed: 12662003
Thorax. 1999 Jul;54(7):611-3
pubmed: 10377206
Eur Respir J. 2009 Nov;34(5):1046-51
pubmed: 19574326
Allergy. 2019 Sep;74(9):1703-1715
pubmed: 31021427
Prim Care Respir J. 2013 Mar;22(1):64-71
pubmed: 23299455
Thorax. 2002 Oct;57(10):875-9
pubmed: 12324674
Obesity (Silver Spring). 2008 Jan;16(1):146-52
pubmed: 18223627
Eur Clin Respir J. 2017 Jun 16;4(1):1334508
pubmed: 28680543
Pediatrics. 2001 Mar;107(3):E37
pubmed: 11230618
Chest. 2000 Nov;118(5):1315-21
pubmed: 11083680
Thorax. 2015 Jul;70(7):659-67
pubmed: 25934136
J Allergy Clin Immunol. 2018 Jan;141(1):104-109.e3
pubmed: 28438546
Clin Exp Allergy. 2017 Nov;47(11):1426-1435
pubmed: 28608416
Pediatrics. 2013 Aug;132(2):e435-42
pubmed: 23897917
Eur Respir J. 2011 Sep;38(3):594-602
pubmed: 21310876
Respir Med. 2007 Nov;101(11):2370-7
pubmed: 17689949
Thorax. 2011 Jun;66(6):508-13
pubmed: 21450787
J Asthma. 2011 Jun;48(5):490-4
pubmed: 21486195
J Asthma Allergy. 2012;5:21-6
pubmed: 22791994
Eur Respir J. 2007 Jul;30(1):62-5
pubmed: 17360725
Obes Rev. 2015 Oct;16(10):883-901
pubmed: 26114839
Lancet Respir Med. 2017 Mar;5(3):224-234
pubmed: 27666650
Am J Respir Crit Care Med. 1997 Apr;155(4):1267-72
pubmed: 9105065
Respir Med. 2008 Dec;102(12):1730-6
pubmed: 18760582
N Engl J Med. 2003 Oct 9;349(15):1414-22
pubmed: 14534334
Respir Med. 2016 Aug;117:223-9
pubmed: 27492535